NCT07221357 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07221357
Title	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	colorectal adenocarcinoma
Therapies	BNT327 + Fluorouracil + Leucovorin + Oxaliplatin BNT327 + Fluorouracil + Irinotecan + Leucovorin BNT327 + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

Additional content available in CKB BOOST